Posner Andrew D, Sultan Samuel T, Zaghloul Norann A, Twaddell William S, Bruno David A, Hanish Steven I, Hutson William R, Hebert Laci, Barth Rolf N, LaMattina John C
University of Maryland School of Medicine, Baltimore, MD, USA.
Division of Transplantation, University of Maryland School of Medicine, Baltimore, MD, USA.
Clin Transplant. 2017 Sep;31(9). doi: 10.1111/ctr.13032. Epub 2017 Jul 13.
Transplant surgeons conventionally select against livers displaying high degrees (>30%) of macrosteatosis (MaS), out of concern for primary non-function or severe graft dysfunction. As such, there is relatively limited experience with such livers, and the natural history remains incompletely characterized. We present our experience of transplanted livers with high degrees of MaS and microsteatosis (MiS), with a focus on the histopathologic and clinical outcomes.
Twenty-nine cases were identified with liver biopsies available from both the donor and the corresponding liver transplant recipient. Donor liver biopsies displayed either MaS or MiS ≥15%, while all recipients received postoperative liver biopsies for cause.
The mean donor MaS and MiS were 15.6% (range 0%-60%) and 41.3% (7.5%-97.5%), respectively. MaS decreased significantly from donor (M=15.6%) to recipient postoperative biopsies (M=0.86%), P<.001. Similarly, MiS decreased significantly from donor biopsies (M=41.3%) to recipient postoperative biopsies (M=1.8%), P<.001. At a median of 68 days postoperatively (range 4-384), full resolution of MaS and MiS was observed in 27 of 29 recipients.
High degrees of MaS and MiS in donor livers resolve in recipients following liver transplantation. Further insight into the mechanisms responsible for treating fatty liver diseases could translate into therapeutic targets.
出于对原发性无功能或严重移植物功能障碍的担忧,移植外科医生通常会排除那些显示出高度(>30%)大泡性脂肪变性(MaS)的肝脏。因此,对于此类肝脏的经验相对有限,其自然病史仍未完全明确。我们介绍了我们在移植高度MaS和小泡性脂肪变性(MiS)肝脏方面的经验,重点关注组织病理学和临床结果。
确定了29例病例,供体和相应肝移植受者均有肝活检样本。供体肝活检显示MaS或MiS≥15%,而所有受者均因病因接受术后肝活检。
供体MaS和MiS的平均值分别为15.6%(范围0%-60%)和41.3%(7.5%-97.5%)。MaS从供体(中位数=15.6%)到受者术后活检(中位数=0.86%)显著下降,P<0.001。同样,MiS从供体活检(中位数=41.3%)到受者术后活检(中位数=1.8%)也显著下降,P<0.001。术后中位68天(范围4-384天)时,29例受者中有27例MaS和MiS完全消退。
肝移植后供体肝脏中的高度MaS和MiS在受者中消退。对治疗脂肪肝疾病机制的进一步了解可能会转化为治疗靶点。